Foundation Medicine Inc (FMI) 48.71 $FMI
OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer
PR Newswire - Mon Apr 20, 7:30AM CDT
OpGen, Inc., a molecular testing and bioinformatics company, today announced the expansion of its executive management team with the appointments of former Foundation Medicine (NASDAQ: FMI) executive Kevin Krenitsky, M.D. as president, and Timothy C. Dec as interim chief financial officer.
FMI: 48.71 (-0.96), OPGN: ()
Foundation Medicine and Collaborators to Present New Data in 12 Oral and Poster Presentations at the AACR Annual Meeting
Business Wire - Mon Apr 20, 6:05AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 12 oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2015 taking place April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.
FMI: 48.71 (-0.96)
Foundation Medicine Announces Its Collaboration with the National Cancer Institute on Exceptional Responders Initiative
Business Wire - Mon Apr 20, 6:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it has entered into a Collaboration Agreement with the National Cancer Institute (NCI) on the Exceptional Responders Initiative (ERI), a nationwide research study to further understand the molecular underpinnings that may lead to exceptional responses to drug therapies in patients with cancer. In this exploratory NCI-led study that includes participation from Baylor College of Medicine, Nationwide Children's Hospital and Foundation Medicine, tumor samples collected from individuals prior to initiation of the therapy of interest, in addition to pertinent clinical data from each patient, will be obtained from more than 300 patients identified as exceptional responders. The samples will be analyzed to determine whether novel therapeutic vulnerabilities can be identified. The outcomes from the ERI could improve the biologic and genomic understandings of cancer and ultimately lead to the enhancement of existing cancer assays and/or the development of new ones that could inform targeted therapeutic treatments and potentially improve clinical outcomes for a greater number of cancer patients.
FMI: 48.71 (-0.96)
Foundation Medicine Announces Timing for First Quarter 2015 Financial Results and Conference Call
Business Wire - Tue Apr 14, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2015 will be released on Monday, May 11, 2015. The management team will host a conference call discussing the company's financial results and recent developments on Monday, May 11, 2015, at 4:30 p.m. ET. The call can be accessed by dialing 1-855-420-0652 (domestic) or 1-484-365-2939 (international) five minutes prior to the start of the call and providing the passcode 22125798.
FMI: 48.71 (-0.96)
InsiderInsights.com Daily Round Up 4/9/15: OVAS, AGCO, OPK, OGES
InsiderInsights - at Seeking Alpha - Fri Apr 10, 8:58AM CDT
ASH: 127.06 (+0.15), STFC: 23.83 (-0.01), MNST: 139.91 (+0.06), OVAS: 29.85 (-0.24), CERU: 5.99 (-0.20), AGCO: 48.16 (-0.16), GIII: 116.32 (-1.15), ASTI: 1.07 (+0.04), PANW: 153.87 (-0.50), TNET: 35.45 (-0.54), DRI: 65.20 (-0.09), FMI: 48.71 (-0.96), LNKD: 259.35 (+0.93), OPK: 14.60 (+0.17), DWRE: 65.40 (+1.36), RAVN: 20.69 (-0.04), TWTR: 51.73 (+0.41)
Roche announces preliminary results of tender offer for Foundation Medicine, Inc.
M2 - Wed Apr 08, 4:44AM CDT
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the preliminary results of the tender offer by Roche Holdings, Inc., its wholly owned subsidiary, for up to 15,604,288 shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at USD 50.00 per share in cash. The tender offer expired at 12:00 midnight, New York City time, at the end of the day on 6 April 2015 and was not extended.
FMI: 48.71 (-0.96)
Foundation Medicine and Roche Complete Strategic Transaction to Advance Molecular Information and Precision Medicine in Oncology
Business Wire - Tue Apr 07, 8:50AM CDT
--Roche Gains Minority Board Representation and Becomes Majority Shareholder in Foundation Medicine
FMI: 48.71 (-0.96)
'Mad Money' Lightning Round: I'm No Fan of World Wrestling Entertainment
at The Street - Tue Apr 07, 5:00AM CDT
Cramer is staying away from Juno Therapeutics and Foundation Medicine.
FMI: 48.71 (-0.96), WWE: 14.19 (+0.04), CBB: 3.59 (+0.03), JUNO: 55.72 (-0.68)
Too Many Secondaries In Biotech - Cramer's Lightning Round (4/6/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Apr 07, 4:37AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 6. Bullish Call: Cincinnati Bell (NYSE: CBB ): "What a hammering that has had. I don't know, it's just a call on the comeback of Cincinnati...
FMI: 48.71 (-0.96), WWE: 14.19 (+0.04), CBB: 3.59 (+0.03), JUNO: 55.72 (-0.68), PRTA: 36.96 (+0.36)
Jim Cramer's 'Mad Money' Recap: Weak Unemployment Is Good for Stocks
at The Street - Mon Apr 06, 7:26PM CDT
It's time to accept the fact the futures are often wrong, Cramer says.
KO: 41.31 (+0.53), MNST: 139.91 (+0.06), ZBRA: 97.08 (+0.12), WWE: 14.19 (+0.04), GMCR: 114.53 (+2.27), EMR: 58.15 (-0.07), CBB: 3.59 (+0.03), WFC: 54.67 (+0.39), KMX: 70.84 (-0.04), MSI: 61.59 (+0.16), FMI: 48.71 (-0.96), GM: 37.16 (unch), JUNO: 55.72 (-0.68), PG: 83.09 (+0.01), MSFT: 42.99 (+0.36), VZ: 49.57 (+0.40)
Foundation Medicine shareholders OK Roche tender offer
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 11:45AM CDT
FMI: 48.71 (-0.96)
Foundation Medicine Stockholders Approve Pending Roche Transaction at Special Meeting of Stockholders
Business Wire - Thu Apr 02, 11:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that its stockholders approved each proposal presented at the special meeting of stockholders held on April 2, 2015, in connection with the pending strategic transaction with Roche. More than 78% of the total outstanding shares of common stock eligible to vote at the meeting, and more than 99% of the shares voted at the meeting, were voted in favor of each proposal related to the Roche transaction. The stockholder approval of these proposals satisfies one of the remaining closing conditions for the proposed transaction. The transaction with Roche includes the pending tender offer by Roche to purchase up to 15.6 million shares of Foundation Medicine common stock at a price of $50 per share, and the purchase by Roche of 5 million newly issued shares of Foundation Medicine common stock at a price of $50 per share. The transaction with Roche also includes research & development and commercial collaborations between the parties.
FMI: 48.71 (-0.96)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Foundation Medicine and Collaborators to Present New Data in 20 Oral and Poster Presentations at the 2015 USCAP Annual Meeting
Business Wire - Mon Mar 23, 6:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 20 oral and poster presentations at the 2015 United States & Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 21-27, 2015 in Boston. The company's molecular information products, FoundationOne(R) for solid tumors and FoundationOne(R) Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer. The data to be presented at USCAP provide further evidence of the clinical utility of Foundation Medicine's comprehensive genomic profiles to complement standard-of-care pathology testing to inform the treatment of cancer patients, support coverage and value-based payment by payers, and aid in the development of targeted therapies. Specifically, the collective data will demonstrate:
FMI: 48.71 (-0.96)
Foundation Medicine Announces Executive Promotions and Expanded Leadership Team to Complement Global Growth Initiatives
Business Wire - Mon Mar 23, 5:40AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced four executive promotions and a new leadership appointment to support and accelerate the company's United States and global commercial and operational growth plans.
FMI: 48.71 (-0.96)
Foundation Medicine Announces Proposed Changes to its Board of Directors in Connection with the Pending Roche Transaction
Business Wire - Mon Mar 23, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced proposed changes to its Board of Directors in connection with its pending strategic collaboration with Roche.
FMI: 48.71 (-0.96)
Cancer Advance Boston Brings Together Leading Oncology Experts on April 13th and 14th
PRWeb - Thu Mar 19, 8:04AM CDT
Panels will discuss compassionate use, immunotherapy (including T cell therapy), combination therapy, building successful partnerships, biomarkers and more. Panelists include Rafael Amado (Adaptimmune), Lew Cantley (Meyer Cancer Center at Weill Cornell), George Demetri (Dana Farber Cancer Institute), JC Gutierrez-Ramos (Pfizer), Tyler Jacks (MIT Koch Institute), Patrick Mahaffy (Clovis Oncology), Michael Pellini (Foundation Medicine), Michael Rosenblatt (Merck), Phil Sharp (MIT), Markus Warmuth (H3 Biomedicine) and Richard Wooster (Blend Therapeutics), among others. Leading investors from Bain Capital, Wellington Management Company, Pioneer Investments, Deerfield Partners, Fidelity Investments, Sofinnova Ventures, and Third Rock Ventures will also be in attendance.
FMI: 48.71 (-0.96), CLVS: 85.04 (-1.36), MRK: 57.69 (+0.03)
Roche extends expiration of tender offer for Foundation Med shares
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 9:10AM CST
FMI: 48.71 (-0.96)
Foundation Medicine's (FMI) CEO Michael Pellini on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 9:37PM CST
FMI: 48.71 (-0.96)
OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer
PR Newswire - Mon Apr 20, 7:30AM CDT
OpGen, Inc., a molecular testing and bioinformatics company, today announced the expansion of its executive management team with the appointments of former Foundation Medicine (NASDAQ: FMI) executive Kevin Krenitsky, M.D. as president, and Timothy C. Dec as interim chief financial officer.
FMI: 48.71 (-0.96), OPGN: ()
Foundation Medicine and Collaborators to Present New Data in 12 Oral and Poster Presentations at the AACR Annual Meeting
Business Wire - Mon Apr 20, 6:05AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 12 oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2015 taking place April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.
FMI: 48.71 (-0.96)
Foundation Medicine Announces Its Collaboration with the National Cancer Institute on Exceptional Responders Initiative
Business Wire - Mon Apr 20, 6:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it has entered into a Collaboration Agreement with the National Cancer Institute (NCI) on the Exceptional Responders Initiative (ERI), a nationwide research study to further understand the molecular underpinnings that may lead to exceptional responses to drug therapies in patients with cancer. In this exploratory NCI-led study that includes participation from Baylor College of Medicine, Nationwide Children's Hospital and Foundation Medicine, tumor samples collected from individuals prior to initiation of the therapy of interest, in addition to pertinent clinical data from each patient, will be obtained from more than 300 patients identified as exceptional responders. The samples will be analyzed to determine whether novel therapeutic vulnerabilities can be identified. The outcomes from the ERI could improve the biologic and genomic understandings of cancer and ultimately lead to the enhancement of existing cancer assays and/or the development of new ones that could inform targeted therapeutic treatments and potentially improve clinical outcomes for a greater number of cancer patients.
FMI: 48.71 (-0.96)
Foundation Medicine Announces Timing for First Quarter 2015 Financial Results and Conference Call
Business Wire - Tue Apr 14, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2015 will be released on Monday, May 11, 2015. The management team will host a conference call discussing the company's financial results and recent developments on Monday, May 11, 2015, at 4:30 p.m. ET. The call can be accessed by dialing 1-855-420-0652 (domestic) or 1-484-365-2939 (international) five minutes prior to the start of the call and providing the passcode 22125798.
FMI: 48.71 (-0.96)
InsiderInsights.com Daily Round Up 4/9/15: OVAS, AGCO, OPK, OGES
InsiderInsights - at Seeking Alpha - Fri Apr 10, 8:58AM CDT
ASH: 127.06 (+0.15), STFC: 23.83 (-0.01), MNST: 139.91 (+0.06), OVAS: 29.85 (-0.24), CERU: 5.99 (-0.20), AGCO: 48.16 (-0.16), GIII: 116.32 (-1.15), ASTI: 1.07 (+0.04), PANW: 153.87 (-0.50), TNET: 35.45 (-0.54), DRI: 65.20 (-0.09), FMI: 48.71 (-0.96), LNKD: 259.35 (+0.93), OPK: 14.60 (+0.17), DWRE: 65.40 (+1.36), RAVN: 20.69 (-0.04), TWTR: 51.73 (+0.41)
Roche announces preliminary results of tender offer for Foundation Medicine, Inc.
M2 - Wed Apr 08, 4:44AM CDT
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the preliminary results of the tender offer by Roche Holdings, Inc., its wholly owned subsidiary, for up to 15,604,288 shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at USD 50.00 per share in cash. The tender offer expired at 12:00 midnight, New York City time, at the end of the day on 6 April 2015 and was not extended.
FMI: 48.71 (-0.96)
Foundation Medicine and Roche Complete Strategic Transaction to Advance Molecular Information and Precision Medicine in Oncology
Business Wire - Tue Apr 07, 8:50AM CDT
--Roche Gains Minority Board Representation and Becomes Majority Shareholder in Foundation Medicine
FMI: 48.71 (-0.96)
'Mad Money' Lightning Round: I'm No Fan of World Wrestling Entertainment
at The Street - Tue Apr 07, 5:00AM CDT
Cramer is staying away from Juno Therapeutics and Foundation Medicine.
FMI: 48.71 (-0.96), WWE: 14.19 (+0.04), CBB: 3.59 (+0.03), JUNO: 55.72 (-0.68)
Too Many Secondaries In Biotech - Cramer's Lightning Round (4/6/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Apr 07, 4:37AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 6. Bullish Call: Cincinnati Bell (NYSE: CBB ): "What a hammering that has had. I don't know, it's just a call on the comeback of Cincinnati...
FMI: 48.71 (-0.96), WWE: 14.19 (+0.04), CBB: 3.59 (+0.03), JUNO: 55.72 (-0.68), PRTA: 36.96 (+0.36)
Jim Cramer's 'Mad Money' Recap: Weak Unemployment Is Good for Stocks
at The Street - Mon Apr 06, 7:26PM CDT
It's time to accept the fact the futures are often wrong, Cramer says.
KO: 41.31 (+0.53), MNST: 139.91 (+0.06), ZBRA: 97.08 (+0.12), WWE: 14.19 (+0.04), GMCR: 114.53 (+2.27), EMR: 58.15 (-0.07), CBB: 3.59 (+0.03), WFC: 54.67 (+0.39), KMX: 70.84 (-0.04), MSI: 61.59 (+0.16), FMI: 48.71 (-0.96), GM: 37.16 (unch), JUNO: 55.72 (-0.68), PG: 83.09 (+0.01), MSFT: 42.99 (+0.36), VZ: 49.57 (+0.40)
Foundation Medicine shareholders OK Roche tender offer
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 11:45AM CDT
FMI: 48.71 (-0.96)
Foundation Medicine Stockholders Approve Pending Roche Transaction at Special Meeting of Stockholders
Business Wire - Thu Apr 02, 11:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that its stockholders approved each proposal presented at the special meeting of stockholders held on April 2, 2015, in connection with the pending strategic transaction with Roche. More than 78% of the total outstanding shares of common stock eligible to vote at the meeting, and more than 99% of the shares voted at the meeting, were voted in favor of each proposal related to the Roche transaction. The stockholder approval of these proposals satisfies one of the remaining closing conditions for the proposed transaction. The transaction with Roche includes the pending tender offer by Roche to purchase up to 15.6 million shares of Foundation Medicine common stock at a price of $50 per share, and the purchase by Roche of 5 million newly issued shares of Foundation Medicine common stock at a price of $50 per share. The transaction with Roche also includes research & development and commercial collaborations between the parties.
FMI: 48.71 (-0.96)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Foundation Medicine and Collaborators to Present New Data in 20 Oral and Poster Presentations at the 2015 USCAP Annual Meeting
Business Wire - Mon Mar 23, 6:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 20 oral and poster presentations at the 2015 United States & Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 21-27, 2015 in Boston. The company's molecular information products, FoundationOne(R) for solid tumors and FoundationOne(R) Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer. The data to be presented at USCAP provide further evidence of the clinical utility of Foundation Medicine's comprehensive genomic profiles to complement standard-of-care pathology testing to inform the treatment of cancer patients, support coverage and value-based payment by payers, and aid in the development of targeted therapies. Specifically, the collective data will demonstrate:
FMI: 48.71 (-0.96)
Foundation Medicine Announces Executive Promotions and Expanded Leadership Team to Complement Global Growth Initiatives
Business Wire - Mon Mar 23, 5:40AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced four executive promotions and a new leadership appointment to support and accelerate the company's United States and global commercial and operational growth plans.
FMI: 48.71 (-0.96)
Foundation Medicine Announces Proposed Changes to its Board of Directors in Connection with the Pending Roche Transaction
Business Wire - Mon Mar 23, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced proposed changes to its Board of Directors in connection with its pending strategic collaboration with Roche.
FMI: 48.71 (-0.96)
Cancer Advance Boston Brings Together Leading Oncology Experts on April 13th and 14th
PRWeb - Thu Mar 19, 8:04AM CDT
Panels will discuss compassionate use, immunotherapy (including T cell therapy), combination therapy, building successful partnerships, biomarkers and more. Panelists include Rafael Amado (Adaptimmune), Lew Cantley (Meyer Cancer Center at Weill Cornell), George Demetri (Dana Farber Cancer Institute), JC Gutierrez-Ramos (Pfizer), Tyler Jacks (MIT Koch Institute), Patrick Mahaffy (Clovis Oncology), Michael Pellini (Foundation Medicine), Michael Rosenblatt (Merck), Phil Sharp (MIT), Markus Warmuth (H3 Biomedicine) and Richard Wooster (Blend Therapeutics), among others. Leading investors from Bain Capital, Wellington Management Company, Pioneer Investments, Deerfield Partners, Fidelity Investments, Sofinnova Ventures, and Third Rock Ventures will also be in attendance.
FMI: 48.71 (-0.96), CLVS: 85.04 (-1.36), MRK: 57.69 (+0.03)
Roche extends expiration of tender offer for Foundation Med shares
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 9:10AM CST
FMI: 48.71 (-0.96)
Foundation Medicine's (FMI) CEO Michael Pellini on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 9:37PM CST
FMI: 48.71 (-0.96)
